Last updated: February 16, 2026
Product Overview
NDC 67457-0593 corresponds to Obinutuzumab (Gazyva), licensed for treatment of chronic lymphocytic leukemia (CLL) and follicular non-Hodgkin lymphoma (NHL). Manufactured by Roche, Gazyva was approved by the FDA in 2013. Its patent protection is expected to expire around 2030, with biosimilar competition anticipated thereafter.
Market Landscape
Current Market Size
The global oncology monoclonal antibody (mAb) market, including Gazyva, exceeds $25 billion in 2022, with the non-Hodgkin lymphoma segment comprising approximately 20%. The U.S. accounts for about 45% of this market, which translates to an estimated $2.25 billion for Gazyva’s segment in 2022, considering its market share of roughly 10-12%.
Competitive Environment
Key competitors include Rituximab (Rituxan), Obinutuzumab biosimilars, and newer agents like Tafasitamab. Rituximab remains the dominant mAb for CLL and NHL, with sales exceeding $6 billion annually. The entry of biosimilars post-2030 is expected to significantly influence pricing and market share.
Pricing Dynamics
- U.S. Price Point: The average wholesale price (AWP) for Gazyva per infusion ranges between $10,000 and $15,000, depending on dosing and formulation complexity.
- Cost per Treatment: Typical treatment involves 6-8 infusions over several months, leading to an estimated treatment cost of $60,000 to $120,000 per patient per course.
- Reimbursement Rates: Insurance reimbursements typically align with AWP minus negotiated discounts, with net payer costs approximately 20-30% below AWP.
Historical and Projected Price Trends
Historical Trends (2013–2022)
- Initial pricing for Gazyva was approximately $8,000 per infusion.
- Price adjustments have ranged from 2% to 5% annually, driven by inflation, manufacturing costs, and competitive pressures.
- Prescriptions increased annually by an average of 8%, reflecting expanded indications and adoption.
Forecasted Pricing (2023–2033)
- Short-term (2023–2025): Prices are expected to stabilize with incremental increases of 2-3%, as monopolistic pricing persists before biosimilar entry.
- Mid-term (2026–2030): Prices may decline marginally (5-10%) as biosimilars gain approval and market penetration accelerates.
- Post-patent expiration (~2030): Price drops of 50-70% are projected with biosimilar competition, aligning with trends observed for other monoclonal agents, such as infliximab and rituximab.
Factors Influencing Price Projection
- Patent and Regulatory Milestones: Patent expiry around 2030 will permit biosimilar market entries.
- Biosimilar Development: Over 10 biosimilar candidates are in late-stage development for Obinutuzumab, with a high likelihood of approval.
- Market Penetration of Biosimilars: Historically, biosimilars capture 60-90% of the reference product’s market within 3-5 years post-approval.
- Healthcare Policy and Reimbursement: CMS and private insurers will influence final patient access prices, potentially accelerating price reductions.
Impacts of Biosimilar Entry
| Attribute |
Current Gazyva Price |
Biosimilar Entry Post-2030 |
Expected Price Reduction |
| Per infusion |
$12,000 |
$4,800 |
60-70% decrease |
| Treatment course (average) |
$72,000 |
$28,800 |
Approximate reduction |
| Market share |
10-12% |
Dominated by biosimilars |
~80-90% biosimilar share post-entry |
Market Growth Projections
- Estimated CAGR (compound annual growth rate) for Gazyva's market segments before biosimilar competition: 4-6% annually.
- Post-2030, due to biosimilar erosion, market volume may decline sharply, with nominal revenues dropping by up to 70% within five years of biosimilar entry.
Conclusion
Gazyva (NDC 67457-0593) remains a high-cost, high-revenue asset in CLL and NHL treatment. Prices are likely to remain stable until 2030, after which biosimilar competition will exert downward pressure, reducing costs substantially. The strategic focus should include preparing for biosimilar adoption and evaluating new indications to sustain revenue streams.
Key Takeaways
- Gazyva's market value in 2022 sits around $2.25 billion in the U.S.
- Current pricing is approximately $10,000–$15,000 per infusion.
- Price stability is expected until patent expiry (~2030), followed by steep declines due to biosimilar competition.
- Biosimilar entry could lower treatment costs by about 70% and capture significant market share.
- Market growth depends heavily on regulatory developments, reimbursement policies, and adoption rates of biosimilars.
FAQs
-
When will biosimilar versions of Gazyva become available?
Biosimilar applications are in late-stage development, with FDA approval anticipated around 2029–2030, aligning with patent expiration.
-
How will biosimilar competition affect Gazyva’s market share?
Biosimilars are projected to gain 60-90% of the market within 3–5 years of approval, significantly reducing Gazyva’s revenue.
-
What are the key factors influencing future drug prices?
Patent status, biosimilar approval, reimbursement policies, and physician adoption influence pricing dynamics.
-
What is the current average treatment cost of Gazyva?
Approximately $60,000–$120,000 per treatment course, depending on dosing and infusion frequency.
-
Are there emerging alternatives to Gazyva?
New targeted therapies and immunotherapies under development may impact the market, but current standard care remains dominated by monoclonal antibodies.
Citations
- EvaluatePharma. (2022). Oncology Market Report.
- FDA. (2013). Approval of Gazyva.
- IQVIA. (2022). Biopharma Market Analysis.
- U.S. Patent and Trademark Office. (2023). Patent Expiry Data.
- MarketWatch. (2022). Biosimilar Landscape Analysis.
